v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Mar. 28, 2026
Mar. 29, 2025
Mar. 30, 2024
Cash Flows from Operating Activities:      
Net income $ 97,308 $ 167,679 $ 117,558
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 111,717 115,586 97,215
Amortization of fair value inventory step-up 5,814 14,956 3,347
Share-based compensation expense 33,827 29,636 28,332
Impairment of intangible assets 86,546 2,391 10,419
Gain on repurchase of convertible senior notes, net 0 (12,600) 0
Gains on sales of property, plant and equipment (714) (15,698) (1,013)
Remeasurement of contingent consideration (1,879) (23,022) 0
Deferred income taxes (26,471) (5,219) (11,039)
Other non-cash operating activities 10,726 9,978 11,633
Change in operating assets and liabilities:      
Change in accounts receivable (14,881) 6,956 (24,193)
Change in inventories 47,361 (64,704) (60,061)
Change in prepaid income taxes (4,534) 226 (983)
Change in other assets and other liabilities (35,028) (25,232) (34,046)
Change in accounts payable and accrued expenses (16,571) (19,208) 44,582
Net cash provided by operating activities 293,221 181,725 181,751
Cash Flows from Investing Activities:      
Capital expenditures (32,780) (39,278) (38,125)
Proceeds from divestiture and sale of assets 0 43,291 1,500
Proceeds from sale of property, plant and equipment 1,375 23,253 1,810
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (51,891) (21,112) (28,171)
Acquisitions 60,180 150,906 243,852
Other investments (36,071) (17,143) (15,551)
Net cash used in investing activities (179,547) (161,895) (322,389)
Cash Flows from Financing Activities:      
Proceeds from issuance of convertible notes 0 700,000 0
Repayment and repurchase of convertible notes (300,000) (185,500) 0
Purchase of capped call related to convertible notes 0 (88,200) 0
Term loan borrowings 0 250,000 0
Term loan redemption 0 (262,500) 0
Repayment of term loan borrowings (6,250) (4,688) (12,250)
Proceeds from revolving facility 300,000 0 110,000
Payments on revolving facility 0 (50,000) (60,000)
Debt issuance costs 0 (23,135) 0
Proceeds from employee stock purchase plan 7,893 8,333 7,214
Cash used to net share settle employee equity awards (5,001) (10,243) (5,885)
Share repurchases (175,000) (225,000) 0
Other financing activities (102) (249) (922)
Net cash (used in) provided by financing activities (178,460) 108,818 38,157
Effect of exchange rates on cash and cash equivalents 3,463 (685) (3,185)
Net Change in Cash and Cash Equivalents (61,323) 127,963 (105,666)
Cash and Cash Equivalents at Beginning of Year 306,763 178,800 284,466
Cash and Cash Equivalents at End of Year 245,440 306,763 178,800
Supplemental Disclosures of Cash Flow Information:      
Interest paid 17,465 16,534 20,901
Income taxes paid 60,665 49,293 52,706
Fair value of previously held equity interest settled in connection with acquisition 47,258 0 0
Settlement of pre-existing loan in connection with acquisition $ 35,812 $ 0 $ 0